LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 161

Search options

  1. Article: ABCD3-I and ABCD2 Scores in a TIA Population with Low Stroke Risk.

    Ildstad, Fredrik / Ellekjær, Hanne / Wethal, Torgeir / Lydersen, Stian / Fjærtoft, Hild / Indredavik, Bent

    Stroke research and treatment

    2021  Volume 2021, Page(s) 8845898

    Abstract: Objectives: We aimed to evaluate the ABCD3-I score and compare it with the ABCD2 score in short- (1 week) and long-term (3 months; 1 year) stroke risk prediction in our post-TIA stroke risk study, MIDNOR TIA.: Materials and methods: We performed a ... ...

    Abstract Objectives: We aimed to evaluate the ABCD3-I score and compare it with the ABCD2 score in short- (1 week) and long-term (3 months; 1 year) stroke risk prediction in our post-TIA stroke risk study, MIDNOR TIA.
    Materials and methods: We performed a prospective, multicenter study in Central Norway from 2012 to 2015, enrolling 577 patients with TIA. In a subset of patients with complete data for both scores (
    Results: Within 1 week, 3 months, and 1 year, 1.0% (
    Conclusions: The ABCD3-I score had limited value in a short-term prediction of subsequent stroke after TIA and did not reliably discriminate between low- and high-risk patients in a long-term follow-up. The ABCD2 score did not predict subsequent stroke accurately at any time point. Since there is a generally lower stroke risk after TIA during the last years, the benefit of these clinical risk scores and their role in TIA management seems limited.
    Language English
    Publishing date 2021-02-25
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2573724-7
    ISSN 2042-0056 ; 2090-8105
    ISSN (online) 2042-0056
    ISSN 2090-8105
    DOI 10.1155/2021/8845898
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Facilitating cells in tolerance induction for kidney transplantation.

    Yolcu, Esma S / Leventhal, Joseph R / Ildstad, Suzanne T

    Current opinion in organ transplantation

    2015  Volume 20, Issue 1, Page(s) 57–63

    Abstract: Purpose of review: To describe the clinical outcomes and science behind a CD8/TCR facilitating cell-based hematopoietic stem cell transplant approach (termed FCRx) to induce tolerance to renal allografts without graft-versus-host disease (GVHD) and ... ...

    Abstract Purpose of review: To describe the clinical outcomes and science behind a CD8/TCR facilitating cell-based hematopoietic stem cell transplant approach (termed FCRx) to induce tolerance to renal allografts without graft-versus-host disease (GVHD) and avoidance of long-term immunosuppressant drugs in living donor kidney transplant recipients.
    Recent findings: Successful solid organ transplantation currently requires the life-long use of medications to suppress the immune system to prevent transplant rejection. Drug-based immunosuppression significantly increases the risk of infection and cancer, as well as being very costly. Development of new therapies to minimize or eliminate entirely the need for antirejection drugs is of great interest to the transplant community. Therapeutic cell transfer for the control of the human immune system represents a compelling approach to reduce or eliminate the need for antirejection drugs.
    Summary: Establishment of durable hematopoietic macrochimerism under nonmyeloablative conditioning is achievable in mismatched recipients using facilitating cells and stem cells obtained from donor mobilized peripheral blood mononuclear cells. Persistently chimeric recipients developed donor-specific tolerance and were weaned off of immunosuppressive drugs over 12 months. They maintained stable renal function without development of acute or chronic GVHD.
    MeSH term(s) Animals ; Graft Rejection/immunology ; Graft vs Host Disease/immunology ; Hematopoietic Stem Cell Transplantation ; Hematopoietic Stem Cells/immunology ; Humans ; Immune Tolerance/immunology ; Kidney Transplantation
    Language English
    Publishing date 2015-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1390429-2
    ISSN 1531-7013 ; 1087-2418
    ISSN (online) 1531-7013
    ISSN 1087-2418
    DOI 10.1097/MOT.0000000000000156
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Regulatory B cells: the new "it" cell.

    Goode, I / Xu, H / Ildstad, S T

    Transplantation proceedings

    2014  Volume 46, Issue 1, Page(s) 3–8

    Abstract: Regulatory B cells (Breg) are a subpopulation of B cells that play a suppressive role in the immune system. The mechanism of how these immune cells perform their effects has been explored by experiments in mice and in humans. Intracellular staining for ... ...

    Abstract Regulatory B cells (Breg) are a subpopulation of B cells that play a suppressive role in the immune system. The mechanism of how these immune cells perform their effects has been explored by experiments in mice and in humans. Intracellular staining for interleukin 10 continues to be a consistent and reproducible method of identifying Breg in mouse and human studies. The lack of Breg is associated with a worsening of several autoimmune diseases such as collagen-induced arthritis, systemic lupus erythematosus, and experimental autoimmune encephalomyelitis in murine studies. The purpose of this review is to provide a concise summary of the role of Breg in the immune system, including the most recently studied cell surface markers associated with Breg, and to describe the role of Breg in the etiology of several autoimmune diseases, the current understanding of Breg development, their role in the development of autoimmune diseases, and their role in inducing tolerance after transplantation.
    MeSH term(s) Animals ; Autoimmune Diseases/immunology ; B-Lymphocytes, Regulatory/cytology ; B-Lymphocytes, Regulatory/physiology ; Cytokines/metabolism ; Humans ; Immune Tolerance ; Mice ; Phenotype ; Transplantation ; Transplants/immunology
    Chemical Substances Cytokines
    Language English
    Publishing date 2014-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 82046-5
    ISSN 1873-2623 ; 0041-1345
    ISSN (online) 1873-2623
    ISSN 0041-1345
    DOI 10.1016/j.transproceed.2013.08.075
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Vascularized composite allotransplantation at a crossroad.

    Ravindra, K V / Xu, H / Ildstad, S T

    Transplantation proceedings

    2011  Volume 43, Issue 9, Page(s) 3501–3503

    Abstract: Vascularized composite allotransplantation is a relatively young field that has shown significant growth in the past decade. The subspecialty offers opportunities that are not available with solid organ transplants. However, the field also faces ... ...

    Abstract Vascularized composite allotransplantation is a relatively young field that has shown significant growth in the past decade. The subspecialty offers opportunities that are not available with solid organ transplants. However, the field also faces significant hurdles in increasing clinical volumes. The development of innovative immune-reduction strategies will likely determine the pace and direction of growth in the field in the years to come.
    MeSH term(s) Animals ; Face/surgery ; Facial Transplantation/trends ; Graft Rejection/immunology ; Graft Rejection/surgery ; Graft Survival/immunology ; Hand/surgery ; Hand Transplantation ; Humans ; Reconstructive Surgical Procedures/methods ; Skin Transplantation/methods ; Transplantation, Homologous/methods
    Language English
    Publishing date 2011-11
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 82046-5
    ISSN 1873-2623 ; 0041-1345
    ISSN (online) 1873-2623
    ISSN 0041-1345
    DOI 10.1016/j.transproceed.2011.10.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Immunology of vascularized composite allotransplantation: a primer for hand surgeons.

    Ravindra, K / Haeberle, M / Levin, L S / Ildstad, S T

    The Journal of hand surgery

    2012  Volume 37, Issue 4, Page(s) 842–850

    Abstract: ... pathways of antigen recognition, the 3 signals for T-cell activation, and mechanisms and types of allograft ... the use of costimulatory blockade, regulatory T cells, and tolerance induction that have resulted ...

    Abstract Vascularized composite allotransplantation is a recent innovation in the fields of transplantation surgery, plastic and reconstructive surgery, and orthopedic surgery. The success of hand and face transplantation has been based on extensive experience in solid organ transplantation. Advances in understanding the immunology of transplantation have had a major role in achieving excellent results in this new field. The purpose of this article is to introduce the basics of human immunology (innate and adaptive systems) and the immunological basis of human transplantation (the importance of human leukocyte antigen, direct and indirect pathways of antigen recognition, the 3 signals for T-cell activation, and mechanisms and types of allograft rejection) and focus on the mode of action of immunosuppressive drugs that have evolved as the mechanisms and pathways for rejection have been defined through research. This includes recent studies involving the use of costimulatory blockade, regulatory T cells, and tolerance induction that have resulted from research in understanding the mechanisms of immune recognition and function.
    MeSH term(s) Adaptive Immunity ; Antigen-Presenting Cells ; Facial Transplantation ; Hand Transplantation ; Humans ; Immunity, Innate ; Major Histocompatibility Complex/immunology ; Receptors, Antigen, T-Cell/immunology ; Self Tolerance ; T-Lymphocytes, Regulatory/immunology ; Transplantation Immunology ; Transplantation, Homologous/immunology
    Chemical Substances Receptors, Antigen, T-Cell
    Language English
    Publishing date 2012-04
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 605716-0
    ISSN 1531-6564 ; 0363-5023
    ISSN (online) 1531-6564
    ISSN 0363-5023
    DOI 10.1016/j.jhsa.2012.01.042
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Xenotransplantation for AIDS.

    Ildstad, S T

    Lancet (London, England)

    1996  Volume 347, Issue 9003, Page(s) 761

    MeSH term(s) Acquired Immunodeficiency Syndrome/therapy ; Animals ; Bone Marrow Transplantation ; Humans ; Papio ; Pennsylvania ; Research ; San Francisco ; Transplantation, Heterologous
    Language English
    Publishing date 1996-03-16
    Publishing country England
    Document type Comment ; Letter
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0140-6736 ; 0023-7507
    ISSN (online) 1474-547X
    ISSN 0140-6736 ; 0023-7507
    DOI 10.1016/s0140-6736(96)90112-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Stroke risk after transient ischemic attack in a Norwegian prospective cohort.

    Ildstad, Fredrik / Ellekjær, Hanne / Wethal, Torgeir / Lydersen, Stian / Sund, Janne Kutschera / Fjærtoft, Hild / Schüler, Stephan / Horn, Jens Wilhelm / Bråthen, Geir / Midtsæther, Ann-Grete / Morsund, Åse Hagen / Lillebø, Marja-Liisa / Seljeseth, Yngve Müller / Indredavik, Bent

    BMC neurology

    2019  Volume 19, Issue 1, Page(s) 2

    Abstract: Background: Transient ischemic attack (TIA) is a risk factor of stroke. Modern treatment regimens and changing risk factors in the population justify new estimates of stroke risk after TIA, and evaluation of the recommended ABCD: Methods: From ... ...

    Abstract Background: Transient ischemic attack (TIA) is a risk factor of stroke. Modern treatment regimens and changing risk factors in the population justify new estimates of stroke risk after TIA, and evaluation of the recommended ABCD
    Methods: From October, 2012, to July, 2014, we performed a prospective, multicenter study in Central Norway, enrolling patients with a TIA within the previous 2 weeks. Our aim was to assess stroke risk at 1 week, 3 months and 1 year after TIA, and to determine the predictive value of the dichotomized ABCD
    Results: Five hundred and seventy-seven patients with TIA were enrolled of which 85% were examined by a stroke specialist within 24 h after symptom onset. The cumulative incidence of stroke within 1 week, 3 months and 1 year of TIA was 0.9% (95% CI, 0.37-2.0), 3.3% (95% CI, 2.1-5.1) and 5.4% (95% CI, 3.9-7.6), respectively. The accuracy of the ABCD
    Conclusions: We found a lower stroke risk after TIA than reported in earlier studies. The ABCD
    Trial registration: Unique identifier: NCT02038725 (retrospectively registered, January 16, 2014).
    MeSH term(s) Humans ; Ischemic Attack, Transient/epidemiology ; Norway/epidemiology ; Prospective Studies ; Risk Factors ; Stroke/epidemiology
    Language English
    Publishing date 2019-01-03
    Publishing country England
    Document type Journal Article ; Multicenter Study
    ISSN 1471-2377
    ISSN (online) 1471-2377
    DOI 10.1186/s12883-018-1225-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Composite tissue allotransplantation: past, present and future-the history and expanding applications of CTA as a new frontier in transplantation.

    Wu, S / Xu, H / Ravindra, K / Ildstad, S T

    Transplantation proceedings

    2009  Volume 41, Issue 2, Page(s) 463–465

    Abstract: Composite tissue allotransplantation (CTA) transplantation is currently being performed with increasing frequency in the clinic. The feasibility of the procedure has been confirmed in over 40 successful hand transplants, 3 facial reconstructions, and ... ...

    Abstract Composite tissue allotransplantation (CTA) transplantation is currently being performed with increasing frequency in the clinic. The feasibility of the procedure has been confirmed in over 40 successful hand transplants, 3 facial reconstructions, and vascularized knee, esophageal, abdominal wall, and tracheal allografts. The toxicity of chronic, nonspecific immunosuppression remains a major limitation to the widespread availability of CTA and is associated with opportunistic infections, nephrotoxicity, end-organ damage, and an increased rate of malignancy. Methods to reduce or eliminate the requirement for immunosuppression would represent a significant step forward in the field. Mixed chimerism induces tolerance to solid organ and tissue allografts, including CTA. This overview focuses on the history and expanding applications of CTA as a new frontier in transplantation, and considers the important hurdles that must be overcome through research to allow widespread clinical application.
    MeSH term(s) Bone Marrow/blood supply ; Bone Marrow Transplantation/immunology ; Facial Transplantation/trends ; Graft Rejection/immunology ; Graft Survival/immunology ; Hand Transplantation ; Humans ; Immunosuppression/methods ; T-Lymphocytes, Regulatory/immunology ; Tissue Transplantation/trends ; Transplantation Chimera ; Transplantation Tolerance/immunology ; Transplantation, Homologous/methods ; Transplantation, Homologous/trends
    Language English
    Publishing date 2009-03-24
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 82046-5
    ISSN 1873-2623 ; 0041-1345
    ISSN (online) 1873-2623
    ISSN 0041-1345
    DOI 10.1016/j.transproceed.2009.01.027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Mixed allogeneic chimerism. Past, present, and prospects for the future.

    Brouha, P C / Ildstad, S T

    Transplantation

    2001  Volume 72, Issue 8 Suppl, Page(s) S36–42

    MeSH term(s) Animals ; Antigen-Presenting Cells/immunology ; Autoimmunity ; Bone Marrow Transplantation/immunology ; Chimera/immunology ; Graft vs Host Disease/etiology ; Humans ; Immune Tolerance ; Isoantigens/immunology ; Transplantation Conditioning ; Transplantation, Homologous
    Chemical Substances Isoantigens
    Language English
    Publishing date 2001-10-27
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S. ; Review
    ZDB-ID 208424-7
    ISSN 1534-6080 ; 0041-1337
    ISSN (online) 1534-6080
    ISSN 0041-1337
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Impact of bone marrow transplantation on type I diabetes.

    Domenick, M A / Ildstad, S T

    World journal of surgery

    2001  Volume 25, Issue 4, Page(s) 474–480

    Abstract: Type I diabetes is a systemic autoimmune disease. Evidence is accumulating that autoimmune diseases such as type I diabetes are linked to the bone marrow hematopoietic stem cell (HSC) itself rather than its derivatives. HSC chimerism achieved through ... ...

    Abstract Type I diabetes is a systemic autoimmune disease. Evidence is accumulating that autoimmune diseases such as type I diabetes are linked to the bone marrow hematopoietic stem cell (HSC) itself rather than its derivatives. HSC chimerism achieved through bone marrow transplantation (BMT) may affect type I diabetes in two ways: first, to induce tolerance to pancreas and islet cell transplants; and second, to reverse the autoimmune process prior to the development of terminal complications. Transplantation of bone marrow from normal donors into patients with hematologic malignancy and coexistent type I diabetes has reversed the systemic diabetic autoimmune process. Donor HSCs can also be utilized for the induction of donor-specific tolerance to islet cell transplants. Islet or whole pancreas transplantation is the most physiologic approach to treating type I diabetes. Currently, this is limited by the requirement for high-dose chronic nonspecific immunosuppression to prevent rejection. Despite these agents, chronic rejection remains the primary cause for late graft loss. Donor-specific tolerance eliminates the requirement for immunosuppression and prevents the development of chronic rejection. Bone marrow transplantation does have limitations. In particular these limitations include the morbidity associated with lethal conditioning, graft-versus-host disease, and failure of engraftment. Currently the morbidity and mortality associated with lethal conditioning could not be justified for tolerance induction or interruption of the autoimmune state in type I diabetes. The goal of current research is to identify those factors in both recipient and donor that optimize engraftment to reverse the risk/benefit ratio associated with BMT. This article reviews the state of the art for HSC chimerism affecting diabetes.
    MeSH term(s) Animals ; Autoimmunity ; Bone Marrow Transplantation/immunology ; Diabetes Mellitus, Type 1/immunology ; Diabetes Mellitus, Type 1/physiopathology ; Diabetes Mellitus, Type 1/surgery ; Graft Rejection/immunology ; Hematopoietic Stem Cell Transplantation ; Humans ; Mosaicism ; Transplantation Conditioning ; Transplantation Tolerance
    Language English
    Publishing date 2001-04
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S. ; Review
    ZDB-ID 224043-9
    ISSN 1432-2323 ; 0364-2313
    ISSN (online) 1432-2323
    ISSN 0364-2313
    DOI 10.1007/s002680020340
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top